Related Experiment Video
Updated: Aug 14, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Tumor Progression, Parallel Mechanisms and Therapeutic Targets
Leif Håkansson1,2, Pontus Dunér3, Annika Håkansson4
1Division of Clinical Tumorimmunology, Department of Oncology, University Hospital of Linkoping, 581 85 Linkoping, Sweden.
Cancers
|August 13, 2026
Summary
Targeting the IL-6-inducing factor (IL-6IF) offers a novel cancer therapy. This approach selectively inhibits pathological IL-6 production, disrupting tumor progression and enhancing anti-tumor immunity.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer progression involves immune dysregulation and tumor-intrinsic factors like hypoxia and IL-6.
- These factors promote angiogenesis, metastasis, immune evasion, and treatment resistance through overlapping pathways.
- Early proteolytic activity and IL-6-inducing factor (IL-6IF) contribute to pathological IL-6 production.
Purpose of the Study:
- To investigate the role of IL-6IF in cancer progression.
- To explore the IL-6/HIF-1α/STAT3 axis in driving tumor growth and immune suppression.
- To evaluate selective IL-6IF inhibition as a therapeutic strategy.
Main Methods:
- Identification of IL-6IF as a protease-generated albumin fragment.
- Analysis of IL-6 feedback loops with HIF-1α and STAT3.
- Assessment of IL-6IF's impact on tumor-promoting mechanisms and anti-tumor immunity.
Main Results:
- IL-6IF triggers pathological IL-6 production, which enhances HIF-1α and STAT3 signaling, promoting glycolysis and lactate accumulation.
- A self-sustaining IL-6/HIF-1α/STAT3 axis drives tumor progression and suppresses anti-tumor immunity.
- Selective IL-6IF inhibition prevents pathological IL-6 production while preserving physiological immune function.
Conclusions:
- IL-6 is a central regulator of metabolic and immunological reprogramming in cancer.
- Targeting IL-6IF offers a novel strategy to disrupt multiple tumor-promoting pathways simultaneously.
- Selective IL-6IF inhibition may improve cancer immunotherapy responsiveness by modulating pathological IL-6 synthesis.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...